Catalyst
Slingshot members are tracking this event:
The first FDA-approved follow-on insulin glargine treatment, BASAGLAR will be available in the U.S. starting on December 15, 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| LLY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 15, 2016
Occurred Source:
https://investor.lilly.com/releasedetail.cfm?ReleaseID=1004325
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Basaglar, Fda, Approval, Abasaglar, Insulin Glargine Injection, Kwikpen
